Continuous vs intermittent adenosine 2A receptor (A2AR) inhibition in preclinical colon cancer (CC) models and in a Phase (Ph) II study of taminadenant (NIR178) + spartalizumab (PDR001) in patients (pts) with non-small cell lung cancer (NSCLC). (October 2020) - Lin, C.C.; Joerger, M.; Grell, P.; Chiappori, A.A.; Leal, T.A.; Kasper, S.; Jerusalem, G.; Gonçalves, A.; Wolf, J.; De Braud, F.; de Jonge, M.J.A.; Otero, J.; et al.